SEC Form 4 · accession 0001193125-26-267671
Corbus Pharmaceuticals Holdings, Inc. · CRBP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John Kenneth Jenkins
Director
Period of report
Jun 10, 2026
Accepted (ET)
Jun 11, 2026 · 4:30 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001595097
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, par value $0.0001 per shareF2,F3 | Jun 10, 2026 | S | 4,800 | $7.9137 | D | 3,833 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 11, 2026.
- F2The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.71 to $7.97. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F3This amount includes 3,800 unvested RSUs subject to the grant's vesting schedule as previously reported.